Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 10/20 | 0.39 |
| ▸ | CA2 | P00918 | 10/20 | 0.39 |
| ▸ | CA9 | Q16790 | 10/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 10/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13972857 | 0.88 | TAS2R14 (0.49) | NPSR1L3MBTL1CA1CA2CA9 | |
| SCHEMBL4552332 | 0.88 | TAS2R14 (0.49) | NPSR1L3MBTL1CA1CA2CA9 | |
| SCHEMBL4410698 | 0.86 | NPSR1 (0.41) | NPSR1L3MBTL1CA1CA2CA9 | |
| SCHEMBL4416809 | 0.86 | MEN1 (0.41) | NPSR1L3MBTL1CA1CA2CA9 | |
| SCHEMBL4417162 | 0.85 | SMN1; SMN2 (0.43) | NPSR1L3MBTL1CA1CA2CA9 | |
| SCHEMBL4413385 | 0.85 | FPR2 (0.37) | NPSR1L3MBTL1CA1CA2CA9 | |
| SCHEMBL13973155 | 0.85 | FPR2 (0.37) | NPSR1L3MBTL1CA1CA2CA9 | |
| SCHEMBL4423028 | 0.84 | CA1 (0.41) | NPSR1L3MBTL1CA1CA2CA9 | |
| SCHEMBL13973317 | 0.84 | CA1 (0.41) | NPSR1L3MBTL1CA1CA2CA9 | |
| SCHEMBL4415190 | 0.84 | CA1 (0.41) | NPSR1L3MBTL1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663983-B1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| EP-1663983-A1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2006-06-07 | — | — | EP | disclosed |
| US-20050070570-A1 | Novel potassium channels modulators | 4SC AG (DE) | 2005-03-31 | — | — | US | disclosed |
| WO-2004113302-A1 | N-SUBSTITUTED 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070570-A1 | Novel potassium channels modulators | HCN4, KCNA4, KCNN4 | NPSR1 155/4885L3MBTL1 2533/4885CA1 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.